CLINICAL TRIAL OF THE DAY

Here, is the CLINICAL TRIAL OF THE DAY
The interesting clinical study with impact on future clinical practice
// Our editor's opinion only //

[CLINICAL TRIAL OF THE DAY @mdwrtcom]

Progression-free survival differed significantly among arbitrarily defined endocrine sensitivity groups in metastatic #breastcancer #SABCS23

[Stephanie Graff, MD, FACP, FASCO @DrSGraff]

Dr. Barrios highlights how very different hormone receptor positive metastatic breast cancer can be—and compares to the Aurora trial’s validation of those definitions #SABCS23 @OncoAlert

[CLINICAL TRIAL OF THE DAY @mdwrtcom]

In hemodynamically unstable brain-dead potential heart donors, intravenous levothyroxine infusion did not result in significantly more hearts being transplanted than saline infusion

https://t.co/vyNvWYZmUT
#DataViz #visualabstract

[CLINICAL TRIAL OF THE DAY @mdwrtcom]

DeLLphi-301 trial: #tarlatamab showed antitumor activity with durable objective responses and promising survival outcomes in patients with previously treated small-cell #lungcancer

https://t.co/vwvi5OPH9r
#DataViz #visualabstract

[CLINICAL TRIAL OF THE DAY @mdwrtcom]

#FLAURA2 trial: first-line treatment with #osimertinib-#chemotherapy led to a significantly longer PFS than osimertinib monotherapy among patients with #EGFR-mutated advanced #NSCLC

https://t.co/6cIUEYOrsS
#visualabstract #DataViz #cancertwi @dplanchard

[CLINICAL TRIAL OF THE DAY @mdwrtcom]

#GRADUATE clinical trials: #gantenerumab led to a lower amyloid plaque burden than placebo in #AlzheimersDisease but was not associated with slower clinical decline

https://t.co/sxzH88RWC5
#visualabstract #DataViz #Alzheimers @Roche

[CLINICAL TRIAL OF THE DAY @mdwrtcom]

#ARTESIA trial: in patients with subclinical #atrialfibrillation, #apixaban resulted in a lower risk of #stroke or #systemicembolism than aspirin but a higher risk of major bleeding

https://t.co/1smlxWO79J
#visualabstract #dataviz #AF

[CLINICAL TRIAL OF THE DAY @mdwrtcom]

#CheckMate 901 trial: #nivolumab plus gemcitabine–cisplatin resulted in significantly better outcomes in patients with previously untreated advanced #urothelialcarcinoma than gemcitabine–cisplatin alone

https://t.co/28hT5RzTLy
#DataViz #visualabstract

[CLINICAL TRIAL OF THE DAY @mdwrtcom]

Spasertan failed to improve focal segmental glomerulosclerosis outcomes compared to irbesartan
https://t.co/3ZWESNVUlT
#VisualAbstract #nephrology #kidney #KidneyTwitter

[CLINICAL TRIAL OF THE DAY @mdwrtcom]

ENVISION trial: in patients with IgA #nephropathy, 12 months of treatment with #sibeprenlimab resulted in a significantly greater decrease in proteinuria than placebo

https://t.co/UHR8DDBAoM
#dataviz #visualabstract @Visterra_Inc #ASN2023 #ASN #kidneyweek @IgAN_JBarratt

[CLINICAL TRIAL OF THE DAY @mdwrtcom]

Final overall survival analysis from KEYNOTE-826 shows sustainable benefit with first-line #pembrolizumab in persistent, recurrent,
or metastatic cervical #cancer
https://t.co/vlmKSNpXcR
#VisualAbstract #oncology

[CLINICAL TRIAL OF THE DAY @mdwrtcom]

Treatment with #thalidomide resulted in a reduction in bleeding in patients with recurrent bleeding due to small-intestinal #angiodysplasia

https://t.co/T42XbRq6To
#visualabstract #dataviz

[CLINICAL TRIAL OF THE DAY @mdwrtcom]

After release of EMBARK trial results the question if failure to fulfill primary endpoint will jeopardize Elevidys™ full approval for Duchenne muscular dystrophy stands
https://t.co/1eFed1EyHC

[CLINICAL TRIAL OF THE DAY @mdwrtcom]

AiDAPT ISRCTN Registry: hybrid closed-loop therapy significantly improved maternal #glycemiccontrol during #pregnancy complicated by type 1 #diabetes

https://t.co/O5m6DmzWVg
#dataviz #visualabstract

[CLINICAL TRIAL OF THE DAY @mdwrtcom]

EV-302/KEYNOTE-A39: #enfortumab vedotin + #pembrolizumab improved overall survival by 53% compared to platinum-based chemotherapy in urothelial #cancer

[Tom Powles @tompowles1]

Enfortumab vedotin & Pembrolizumab improving PFS & OS by 55% & 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%). Chemo has not been beaten before (despite multiple efforts). RR and CR of 68% & 29% is hard to beat. DOR not reached (1/3)#ESMO2023

[CLINICAL TRIAL OF THE DAY @mdwrtcom]

AEGEAN trial: in resectable #NSCLC, perioperative #durvalumab was associated with significantly greater event-free survival and pathological complete response than neoadjuvant chemotherapy alone

https://t.co/3W5eDuOxkR
#visualabstract #dataviz #cancertwi #lungcancer @FouadMD

[CLINICAL TRIAL OF THE DAY @mdwrtcom]

Radulotatug deruxtecan demonstrated impressive response rates in heavily pretreated platinum-resistant #OvarianCancer patients
#VisualAbstract #oncology #cancer #ESMO2023

[CLINICAL TRIAL OF THE DAY @mdwrtcom]

Second interim analysis from LITESPARK-005 Trial demonstrated significant improvement in primary endpoint of progression free survival accompanied by better QoL compared to everolimus treatment in pretreated renal #cancer
#VisualAbstract #oncology #ESMO2023

[CLINICAL TRIAL OF THE DAY @mdwrtcom]

New data from NATALEE trial indicate sustained invasive disease-free survival for adjuvant ribociclib in all major subgroups of early #breastcancer patients
https://t.co/xUKVQ0xvPr
#VisualAbstract #oncology #ESMO23

[CLINICAL TRIAL OF THE DAY @mdwrtcom]

Two short courses of teplizumab allowed to diminish progression of newly diagnosed type 1 #diabetes , yet failed to improve glycemic control
https://t.co/GtzpT6AGwk
#VisualAbstract #endocrinology

[CLINICAL TRIAL OF THE DAY @mdwrtcom]

ATLANTIS trial: titrated low-dose #amitriptyline was superior to placebo as a second-line treatment for #IBS across multiple outcomes, and was safe and well tolerated

https://t.co/Ut44BQBtZb
#visualabstract #dataviz #gastrotwi #Gastroenterology @amanda_horler